Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor has been approved as the second-line antidiabetic therapy and as first-line agents in people who did not tolerate metformin. Linagliptin improves insulin secretion, reduces glucagon production with added advantages of reduced risk of hypoglycemia, weight neutrality, and good safety profile. Linagliptin is excreted mainly via the enterohepatic system and hence suitable for patients with renal impairment without dose adjustment. These additional advantages of linagliptin make it a desirable antidiabetic for patients with cardiac and renal diseases.
1,2 In this regard, Boehringer Ingelheim India and Docplexus have organized an interactive webinar on 18th November 2020 from 03:00 PM IST. In this webinar, the expert panel (Dr. Sujeet Jha and Dr. Uday Jadhav) will give their insights on the role of linagliptin in simplifying glycemic…